Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Buy
71
NUKK Quote, Financials, Valuation and Earnings
Last price:
$15.45
Seasonality move
:
25972.98%
Day range:
$15.55 - $16.50
52-week range:
$1.30 - $78.32
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.75x
P/B ratio:
--
Volume:
57.9K
Avg. volume:
134.8K
1-year change:
138.95%
Market cap:
$77.3M
Revenue:
$5.9M
EPS (TTM):
-$20.40
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Nukkleus has -- downside to fair value with a price target of -- per share.
NUKK vs. S&P 500
-
Over the past 5 trading days, Nukkleus has overperformed the S&P 500 by 11.26% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Nukkleus does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nukkleus revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Nukkleus reported revenues of $175.2K.
Earnings Growth
-
Nukkleus has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Nukkleus reported earnings per share of -$0.88.
Enterprise value:
80.7M
EV / Invested capital:
--
Price / LTM sales:
4.75x
EV / EBIT:
--
EV / Revenue:
13.64x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-21.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$502.5K
Return On Assets:
-581.66%
Net Income Margin (TTM):
-253.45%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-794.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $21.5M | $21.3M | $5.9M | $5.1M | $236.1K | |
| Gross Profit | -$661.4K | -$343.1K | $998.5K | -$278.2K | $217.8K | |
| Operating Income | -$6.8M | -$4.4M | -$7.6M | -$1.2M | -$1M | |
| EBITDA | -$9.2M | -$15M | -$8M | -$13.7M | $4.9M | |
| Diluted EPS | -$0.34 | -$2.79 | -$6.92 | -$0.31 | $2.12 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.8M | $5.1M | $3.7M | $2.9M | $965.7K | |
| Total Assets | $3.8M | $15.8M | $18.4M | $3.4M | $985K | |
| Current Liabilities | $5.2M | $6.7M | $7.5M | $9.1M | $7.1M | |
| Total Liabilities | $5.2M | $6.7M | $7.5M | $9.5M | $8.1M | |
| Total Equity | -$1.4M | $9.2M | $10.9M | -$6.2M | -$7.1M | |
| Total Debt | -- | -- | -- | $420.6K | $4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.6M | -$1.2M | -$3.8M | -$605.7K | -$1.2M | |
| Cash From Investing | -$35K | -$1.1M | $132.8K | -$914.1K | $1.1K | |
| Cash From Financing | -- | $418.3K | $3M | $418.3K | $703.6K | |
| Free Cash Flow | $1.6M | -$1.3M | -$3.8M | -$605.8K | -$1.2M | |
NUKK
Sector
Market Cap
$77.3M
$78.3M
Price % of 52-Week High
20.6%
57.88%
Dividend Yield
0%
0%
Shareholder Yield
--
0.76%
1-Year Price Total Return
138.95%
-18.18%
Beta (5-Year)
--
0.870
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$15.13
200-day SMA
Buy
Level
$10.17
Bollinger Bands (100)
Sell
Level
7.81 - 28.25
Chaikin Money Flow
Buy
Level
29.6M
20-day SMA
Buy
Level
$13.48
Relative Strength Index (RSI14)
Buy
Level
58.09
ADX Line
Buy
Level
20.21
Williams %R
Neutral
Level
-24.8073
50-day SMA
Buy
Level
$14.07
MACD (12, 26)
Buy
Level
0.35
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
293.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-85.0293)
Sell
CA Score
(Annual)
Level (-32.3195)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (71.1448)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).
Stock Forecast FAQ
In the current month, NUKK has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NUKK average analyst price target in the past 3 months is --.
-
Where Will Nukkleus Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nukkleus share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Nukkleus?
Analysts are divided on their view about Nukkleus share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nukkleus is a Sell and believe this share price will rise from its current level to --.
-
What Is Nukkleus's Price Target?
The price target for Nukkleus over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NUKK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nukkleus is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NUKK?
You can purchase shares of Nukkleus via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nukkleus shares.
-
What Is The Nukkleus Share Price Today?
Nukkleus was last trading at $15.45 per share. This represents the most recent stock quote for Nukkleus. Yesterday, Nukkleus closed at $16.13 per share.
-
How To Buy Nukkleus Stock Online?
In order to purchase Nukkleus stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 7.02% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 2.51% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 5.86% over the past day.
